Your browser is no longer supported. Please, upgrade your browser.
Settings
PTI Proteostasis Therapeutics, Inc. daily Stock Chart
PTI [NASD]
Proteostasis Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own17.86% Shs Outstand52.15M Perf Week-3.48%
Market Cap53.81M Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float42.40M Perf Month-17.78%
Income-43.50M PEG- EPS next Q-0.19 Inst Own17.10% Short Float4.72% Perf Quarter-18.98%
Sales0.00M P/S- EPS this Y28.00% Inst Trans-23.78% Short Ratio2.16 Perf Half Y-2.63%
Book/sh0.86 P/B1.29 EPS next Y-9.60% ROA-55.00% Target Price- Perf Year31.36%
Cash/sh1.01 P/C1.10 EPS next 5Y- ROE-75.40% 52W Range0.70 - 4.72 Perf YTD-51.32%
Dividend- P/FCF- EPS past 5Y5.70% ROI-98.00% 52W High-76.48% Beta1.20
Dividend %- Quick Ratio6.70 Sales past 5Y-0.60% Gross Margin- 52W Low58.57% ATR0.09
Employees41 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)37.10 Volatility9.99% 6.95%
OptionableYes Debt/Eq0.02 EPS Q/Q56.50% Profit Margin- Rel Volume0.35 Prev Close1.08
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume927.00K Price1.11
Recom2.30 SMA20-10.74% SMA50-17.62% SMA200-28.16% Volume321,835 Change2.78%
Oct-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-12-17Reiterated Robert W. Baird Outperform $13 → $25
Apr-18-16Initiated Guggenheim Neutral
Mar-07-16Initiated Robert W. Baird Outperform $13
Mar-07-16Initiated RBC Capital Mkts Outperform $20
Mar-07-16Initiated Leerink Partners Outperform
Mar-07-16Initiated H.C. Wainwright Buy $15
Sep-23-20 11:50PM  
03:00PM  
Sep-22-20 06:50PM  
02:14PM  
Sep-17-20 02:50PM  
Sep-16-20 01:19PM  
Sep-15-20 01:33PM  
Sep-14-20 05:28PM  
Sep-12-20 11:00AM  
Sep-10-20 08:50PM  
Sep-05-20 11:10AM  
Sep-04-20 06:23PM  
Sep-03-20 01:10AM  
Sep-02-20 08:00PM  
Aug-29-20 02:11PM  
Aug-28-20 11:50AM  
Aug-27-20 04:35PM  
10:59AM  
Aug-26-20 06:56PM  
06:24PM  
Aug-25-20 06:20PM  
05:05PM  
03:41PM  
12:00PM  
11:04AM  
06:15AM  
Aug-24-20 06:39PM  
06:13PM  
07:00AM  
Aug-06-20 08:20PM  
04:05PM  
Jun-05-20 04:05PM  
Jun-04-20 09:46AM  
Jun-01-20 07:00AM  
May-15-20 05:25PM  
04:10PM  
May-13-20 07:43AM  
May-12-20 09:02AM  
May-06-20 12:30PM  
Apr-24-20 09:29AM  
Apr-13-20 08:00AM  
Mar-10-20 04:36PM  
11:11AM  
Feb-26-20 09:56AM  
Feb-24-20 08:00AM  
Feb-21-20 10:12AM  
Feb-20-20 07:03AM  
Feb-19-20 11:19AM  
Feb-18-20 10:06AM  
Jan-22-20 07:00AM  
Jan-13-20 08:00AM  
Jan-09-20 12:16PM  
Jan-06-20 11:30AM  
Jan-03-20 09:56AM  
Dec-20-19 09:16AM  
Dec-17-19 09:07AM  
07:30AM  
Dec-16-19 02:01PM  
Dec-12-19 09:10AM  
Dec-11-19 07:00AM  
Dec-09-19 08:45AM  
Dec-03-19 07:00AM  
Dec-02-19 07:00AM  
Nov-29-19 12:15PM  
Nov-27-19 08:42AM  
Nov-14-19 01:31PM  
Nov-07-19 04:05PM  
Nov-06-19 07:00AM  
Nov-05-19 10:44AM  
Oct-29-19 10:33AM  
Oct-24-19 07:00AM  
Oct-21-19 07:00AM  
Oct-02-19 09:29AM  
Sep-26-19 07:00AM  
Sep-20-19 01:22PM  
Sep-19-19 04:05PM  
Aug-15-19 03:47PM  
Aug-07-19 06:05PM  
04:05PM  
10:30AM  
Aug-01-19 09:21AM  
Jul-25-19 07:00AM  
Jul-23-19 07:00AM  
Jul-15-19 11:19AM  
Jun-14-19 01:38PM  
Jun-04-19 07:00AM  
Jun-03-19 07:00AM  
May-31-19 08:25AM  
May-15-19 08:00AM  
May-13-19 08:00AM  
May-08-19 08:55PM  
07:47PM  
05:15PM  
May-07-19 10:47AM  
May-02-19 11:04AM  
May-01-19 10:32AM  
Apr-08-19 08:44AM  
Mar-26-19 12:11PM  
12:09PM  
07:36AM  
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
New Enterprise Associates 12, 10% OwnerNov 27Sale2.521,166,7552,941,7394,270,691Nov 29 03:34 PM
New Enterprise Associates 12, 10% OwnerNov 26Sale2.45117,164287,1345,437,446Nov 29 03:34 PM